Overview
- After Jamal Musiala came on as a substitute in Friday’s 1-1 draw with Cologne, supervisory board member Karl‑Heinz Rummenigge publicly said the player’s health makes a full return to his prior level doubtful.
- Musiala was diagnosed this summer with a neurological dysfunction that causes brief, treatable absence seizures and has also missed time with a September muscle tear and a major 2025 injury.
- Reports say managing Musiala’s medication is difficult because drugs that suppress seizures can cause side effects that blunt peak performance, and altering treatment risks recurrence of episodes.
- Bayern have signalled they may seek a sale or a pay renegotiation for Musiala, who is under a contract reported to run to mid‑2030 and to pay about €25m a year, though club leaders acknowledge finding a buyer could be hard.
- FIFPRO has formally criticised Bayern’s public comments as pressure on a recovering player and called for private talks and protection of his welfare while club president Herbert Hainer says Musiala will be supported and further conversations are expected.